BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Marchandet L, Lallier M, Charrier C, Baud'huin M, Ory B, Lamoureux F. Mechanisms of Resistance to Conventional Therapies for Osteosarcoma. Cancers (Basel) 2021;13:683. [PMID: 33567616 DOI: 10.3390/cancers13040683] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 27.0] [Reference Citation Analysis]
Number Citing Articles
1 Pellegrini E, Desando G, Petretta M, Cellamare A, Cristalli C, Pasello M, Manara MC, Grigolo B, Scotlandi K. A 3D Collagen-Based Bioprinted Model to Study Osteosarcoma Invasiveness and Drug Response. Polymers 2022;14:4070. [DOI: 10.3390/polym14194070] [Reference Citation Analysis]
2 Gao X, Gao B, Li S. Extracellular vesicles: A new diagnostic biomarker and targeted drug in osteosarcoma. Front Immunol 2022;13:1002742. [DOI: 10.3389/fimmu.2022.1002742] [Reference Citation Analysis]
3 Van Stiphout CM, Luu AK, Viloria-petit AM. Proteasome Inhibitors and Their Potential Applicability in Osteosarcoma Treatment. Cancers 2022;14:4544. [DOI: 10.3390/cancers14194544] [Reference Citation Analysis]
4 Cui Y, Dong YY. ZCCHC12 promotes the progression of osteosarcoma via PI3K/AKT pathway. Aging (Albany NY) 2022;14. [PMID: 36126191 DOI: 10.18632/aging.204296] [Reference Citation Analysis]
5 Lai HT, Naumova N, Marchais A, Gaspar N, Geoerger B, Brenner C. Insight into the interplay between mitochondria-regulated cell death and energetic metabolism in osteosarcoma. Front Cell Dev Biol 2022;10:948097. [DOI: 10.3389/fcell.2022.948097] [Reference Citation Analysis]
6 Gallego B, Murillo D, Rey V, Huergo C, Estupiñán Ó, Rodríguez A, Tornín J, Rodríguez R. Addressing Doxorubicin Resistance in Bone Sarcomas Using Novel Drug-Resistant Models. Int J Mol Sci 2022;23:6425. [PMID: 35742867 DOI: 10.3390/ijms23126425] [Reference Citation Analysis]
7 Chen T, Liu J, Zhang H, Li J, Shang G. Long Intergenic Noncoding RNA00265 Enhances Cell Viability and Metastasis via Targeting miR-485-5p/USP22 Axis in Osteosarcoma. Front Oncol 2022;12:907472. [DOI: 10.3389/fonc.2022.907472] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Ortal A, Rodríguez A, Solis-Hernández MP, de Prado M, Rey V, Tornín J, Estupiñán Ó, Gallego B, Murillo D, Huergo C, García-Llano JL, Costilla S, Rodríguez R. Proof of concept for the use of trained sniffer dogs to detect osteosarcoma. Sci Rep 2022;12:6911. [PMID: 35484295 DOI: 10.1038/s41598-022-11013-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Alemi F, Malakoti F, Vaghari-Tabari M, Soleimanpour J, Shabestani N, Sadigh AR, Khelghati N, Asemi Z, Ahmadi Y, Yousefi B. DNA damage response signaling pathways as important targets for combination therapy and chemotherapy sensitization in osteosarcoma. J Cell Physiol 2022. [PMID: 35383920 DOI: 10.1002/jcp.30721] [Reference Citation Analysis]
10 Yang C, Tian Y, Zhao F, Huang Q, Liu Z, He C, Li H, Yu li, Miao Z, Qian A. Microtubule actin crosslinking factor 1 functions as a novel therapeutic target in lung metastasis of osteosarcoma. Genes & Diseases 2022. [DOI: 10.1016/j.gendis.2022.03.012] [Reference Citation Analysis]
11 Dong C, Wang Z, Shen P, Chen Y, Wang J, Wang H. Epigallocatechin-3-gallate suppresses the growth of human osteosarcoma by inhibiting the Wnt/β-catenin signalling pathway. Bioengineered 2022;13:8490-502. [PMID: 35348430 DOI: 10.1080/21655979.2022.2051805] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Li Z, Geng M, Ye X, Ji Y, Li Y, Zhang X, Xu W. IRF7 inhibits the Warburg effect via transcriptional suppression of PKM2 in osteosarcoma. Int J Biol Sci 2022;18:30-42. [PMID: 34975316 DOI: 10.7150/ijbs.65255] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Martella E, Dozza B, Ferroni C, Obeyok CO, Guerrini A, Tedesco D, Manet I, Sotgiu G, Columbaro M, Ballestri M, Martini L, Fini M, Lucarelli E, Varchi G, Duchi S. Two Beats One: Osteosarcoma Therapy with Light-Activated and Chemo-Releasing Keratin Nanoformulation in a Preclinical Mouse Model. Pharmaceutics 2022;14:677. [DOI: 10.3390/pharmaceutics14030677] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 De Luca A, Bellavia D, Raimondi L, Carina V, Costa V, Fini M, Giavaresi G. Multiple Effects of Resveratrol on Osteosarcoma Cell Lines. Pharmaceuticals 2022;15:342. [DOI: 10.3390/ph15030342] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Perut F, Graziani G, Roncuzzi L, Zini N, Avnet S, Baldini N. FT-IR Spectral Signature of Sensitive and Multidrug-Resistant Osteosarcoma Cell-Derived Extracellular Nanovesicles. Cells 2022;11:778. [DOI: 10.3390/cells11050778] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Liao Z, Zhang C, Yang T, Liu H, Yang S, Li T, Xing R, Teng S, Yang Y, Zhao J, Zhao G, Bai X, Zhu L, Yang J. Chemotherapy Combined With Recombinant Human Endostatin (Endostar) Significantly Improves the Progression-Free Survival of Stage IV Soft Tissue Sarcomas. Front Oncol 2021;11:778774. [PMID: 35047396 DOI: 10.3389/fonc.2021.778774] [Reference Citation Analysis]
17 Arshad R, Fatima I, Sargazi S, Rahdar A, Karamzadeh-Jahromi M, Pandey S, Díez-Pascual AM, Bilal M. Novel Perspectives towards RNA-Based Nano-Theranostic Approaches for Cancer Management. Nanomaterials (Basel) 2021;11:3330. [PMID: 34947679 DOI: 10.3390/nano11123330] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
18 Mangelinck A, Habel N, Mohr A, Gaspar N, Stefanovska B, Fromigué O. Synergistic Anti-Tumor Effect of Simvastatin Combined to Chemotherapy in Osteosarcoma. Cancers (Basel) 2021;13:5869. [PMID: 34831022 DOI: 10.3390/cancers13225869] [Reference Citation Analysis]
19 Huang C, Lin ZJ, Lee CJ, Lai WH, Chen JC, Huang HC. ε-Viniferin and α-viniferin alone or in combination induced apoptosis and necrosis in osteosarcoma and non-small cell lung cancer cells. Food Chem Toxicol 2021;158:112617. [PMID: 34728247 DOI: 10.1016/j.fct.2021.112617] [Reference Citation Analysis]
20 Zhan F, He T, Chen Z, Zuo Q, Wang Y, Li Q, Zhong S, Ou Y. RhoA enhances osteosarcoma resistance to MPPa-PDT via the Hippo/YAP signaling pathway. Cell Biosci 2021;11:179. [PMID: 34627383 DOI: 10.1186/s13578-021-00690-6] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
21 Lou J, Zhang H, Xu J, Ren T, Huang Y, Tang X, Guo W. circUSP34 accelerates osteosarcoma malignant progression by sponging miR-16-5p. Cancer Sci 2021. [PMID: 34592064 DOI: 10.1111/cas.15147] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Serra M, Hattinger CM, Pasello M, Casotti C, Fantoni L, Riganti C, Manara MC. Impact of ABC Transporters in Osteosarcoma and Ewing's Sarcoma: Which Are Involved in Chemoresistance and Which Are Not? Cells 2021;10:2461. [PMID: 34572110 DOI: 10.3390/cells10092461] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
23 Argenziano M, Tortora C, Pota E, Di Paola A, Di Martino M, Di Leva C, Di Pinto D, Rossi F. Osteosarcoma in Children: Not Only Chemotherapy. Pharmaceuticals (Basel) 2021;14:923. [PMID: 34577623 DOI: 10.3390/ph14090923] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
24 Moonmuang S, Chaiyawat P, Jantrapirom S, Pruksakorn D, Lo Piccolo L. Circulating Long Non-Coding RNAs as Novel Potential Biomarkers for Osteogenic Sarcoma. Cancers 2021;13:4214. [DOI: 10.3390/cancers13164214] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Le T, Su S, Shahriyari L. Investigating Optimal Chemotherapy Options for Osteosarcoma Patients through a Mathematical Model. Cells 2021;10:2009. [PMID: 34440778 DOI: 10.3390/cells10082009] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
26 Hu H, Yang W, Liang Z, Zhou Z, Song Q, Liu W, Deng X, Zhu J, Xing X, Zhong B, Wang B, Wang S, Shao Z, Zhang Y. Amplification of oxidative stress with lycorine and gold-based nanocomposites for synergistic cascade cancer therapy. J Nanobiotechnology 2021;19:221. [PMID: 34315494 DOI: 10.1186/s12951-021-00933-1] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
27 Zheng D, Xia K, Yu L, Gong C, Shi Y, Li W, Qiu Y, Yang J, Guo W. A Novel Six Metastasis-Related Prognostic Gene Signature for Patients With Osteosarcoma. Front Cell Dev Biol 2021;9:699212. [PMID: 34368151 DOI: 10.3389/fcell.2021.699212] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
28 Hattinger CM, Patrizio MP, Fantoni L, Casotti C, Riganti C, Serra M. Drug Resistance in Osteosarcoma: Emerging Biomarkers, Therapeutic Targets and Treatment Strategies. Cancers (Basel) 2021;13:2878. [PMID: 34207685 DOI: 10.3390/cancers13122878] [Cited by in Crossref: 1] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
29 He L, Yang H, Huang J. The tumor immune microenvironment and immune-related signature predict the chemotherapy response in patients with osteosarcoma. BMC Cancer 2021;21:581. [PMID: 34016089 DOI: 10.1186/s12885-021-08328-z] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
30 Le T, Su S, Kirshtein A, Shahriyari L. Data-Driven Mathematical Model of Osteosarcoma. Cancers (Basel) 2021;13:2367. [PMID: 34068946 DOI: 10.3390/cancers13102367] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]